Genetic Diversity of HLA Class I and Class II Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics
Human leukocyte antigen (HLA) class I and II are known to have association with severe cutaneous adverse reactions (SCARs) when exposing to certain drug treatment. Due to genetic differences at population level, drug hypersensitivity reactions are varied, and thus common pharmacogenetics markers for...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.00078/full |
| _version_ | 1819050964183678976 |
|---|---|
| author | Patompong Satapornpong Patompong Satapornpong Patompong Satapornpong Pimonpan Jinda Pimonpan Jinda Thawinee Jantararoungtong Thawinee Jantararoungtong Napatrupron Koomdee Napatrupron Koomdee Chonlawat Chaichan Chonlawat Chaichan Jirawat Pratoomwun Jirawat Pratoomwun Chalitpon Na Nakorn Wichai Aekplakorn Alisa Wilantho Alisa Wilantho Chumpol Ngamphiw Chumpol Ngamphiw Sissades Tongsima Sissades Tongsima Chonlaphat Sukasem Chonlaphat Sukasem Chonlaphat Sukasem |
| author_facet | Patompong Satapornpong Patompong Satapornpong Patompong Satapornpong Pimonpan Jinda Pimonpan Jinda Thawinee Jantararoungtong Thawinee Jantararoungtong Napatrupron Koomdee Napatrupron Koomdee Chonlawat Chaichan Chonlawat Chaichan Jirawat Pratoomwun Jirawat Pratoomwun Chalitpon Na Nakorn Wichai Aekplakorn Alisa Wilantho Alisa Wilantho Chumpol Ngamphiw Chumpol Ngamphiw Sissades Tongsima Sissades Tongsima Chonlaphat Sukasem Chonlaphat Sukasem Chonlaphat Sukasem |
| author_sort | Patompong Satapornpong |
| collection | DOAJ |
| description | Human leukocyte antigen (HLA) class I and II are known to have association with severe cutaneous adverse reactions (SCARs) when exposing to certain drug treatment. Due to genetic differences at population level, drug hypersensitivity reactions are varied, and thus common pharmacogenetics markers for one country might be different from another country, for instance, HLA-A*31:01 is associated with carbamazepine (CBZ)-induced SCARs in European and Japanese while HLA-B*15:02 is associated with CBZ-induced Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) among Taiwanese and Southeast Asian. Such differences pose a major challenge to prevent drug hypersensitivity when pharmacogenetics cannot be ubiquitously and efficiently translated into clinic. Therefore, a population-wide study of the distribution of HLA-pharmacogenetics markers is needed. This work presents a study of Thai HLA alleles on both HLA class I and II genes from 470 unrelated Thai individuals by means of polymerase chain reaction sequence-specific oligonucleotide (PCR-SSO) in which oligonucleotide probes along the stretches of HLA-A, -B, -C, -DRB1, -DQA1, and -DQB1 genes were genotyped. These 470 individuals were selected according to their regional locations, which were from North, Northeast, South, Central, and a capital city, Bangkok. Top ranked HLA alleles in Thai population include HLA-A*11:01 (26.06%), -B*46:01 (14.04%), -C* 01:02 (17.13%), -DRB1*12:02 (15.32%), -DQA1*01:01 (24.89%), and -DQB1*05:02 (21.28%). The results revealed that the distribution of HLA-pharmacogenetics alleles from the South had more HLA-B75 family that a typical HLA-B*15:02 pharmacogenetics test for SJS/TEN screening would not cover. Besides the view across the nation, when compared HLA alleles from Thai population with HLA alleles from both European and Asian countries, the distribution landscape of HLA-associated drug hypersensitivity across many countries could be observed. Consequently, this pharmacogenetics database offers a comprehensive view of pharmacogenetics marker distribution in Thailand that could be used as a reference for other Southeast Asian countries to validate the feasibility of their future pharmacogenetics deployment. |
| first_indexed | 2024-12-21T11:56:24Z |
| format | Article |
| id | doaj.art-7a83c26e4d7b423cb7ffc68d2746528f |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-21T11:56:24Z |
| publishDate | 2020-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-7a83c26e4d7b423cb7ffc68d2746528f2022-12-21T19:04:55ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-02-011110.3389/fphar.2020.00078480312Genetic Diversity of HLA Class I and Class II Alleles in Thai Populations: Contribution to Genotype-Guided TherapeuticsPatompong Satapornpong0Patompong Satapornpong1Patompong Satapornpong2Pimonpan Jinda3Pimonpan Jinda4Thawinee Jantararoungtong5Thawinee Jantararoungtong6Napatrupron Koomdee7Napatrupron Koomdee8Chonlawat Chaichan9Chonlawat Chaichan10Jirawat Pratoomwun11Jirawat Pratoomwun12Chalitpon Na Nakorn13Wichai Aekplakorn14Alisa Wilantho15Alisa Wilantho16Chumpol Ngamphiw17Chumpol Ngamphiw18Sissades Tongsima19Sissades Tongsima20Chonlaphat Sukasem21Chonlaphat Sukasem22Chonlaphat Sukasem23Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, ThailandLaboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, ThailandDivision of General Pharmacy Practice, Department of Pharmaceutical Care, College of Pharmacy, Rangsit University, Pathum Thani, ThailandDivision of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, ThailandLaboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, ThailandDivision of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, ThailandLaboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, ThailandDivision of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, ThailandLaboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, ThailandDivision of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, ThailandLaboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, ThailandDivision of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, ThailandLaboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, ThailandGraduate Program in Translational Medicine, Research Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, ThailandDepartment of Community Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, ThailandNational Biobank of Thailand, National Science and Technology Development Agency, Pathum Thani, ThailandNational Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani, ThailandNational Biobank of Thailand, National Science and Technology Development Agency, Pathum Thani, ThailandNational Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani, ThailandNational Biobank of Thailand, National Science and Technology Development Agency, Pathum Thani, ThailandNational Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani, ThailandDivision of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, ThailandLaboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, ThailandThe Thai Severe Cutaneous Adverse Drug Reaction (THAI-SCAR) Research Group, Bangkok, ThailandHuman leukocyte antigen (HLA) class I and II are known to have association with severe cutaneous adverse reactions (SCARs) when exposing to certain drug treatment. Due to genetic differences at population level, drug hypersensitivity reactions are varied, and thus common pharmacogenetics markers for one country might be different from another country, for instance, HLA-A*31:01 is associated with carbamazepine (CBZ)-induced SCARs in European and Japanese while HLA-B*15:02 is associated with CBZ-induced Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) among Taiwanese and Southeast Asian. Such differences pose a major challenge to prevent drug hypersensitivity when pharmacogenetics cannot be ubiquitously and efficiently translated into clinic. Therefore, a population-wide study of the distribution of HLA-pharmacogenetics markers is needed. This work presents a study of Thai HLA alleles on both HLA class I and II genes from 470 unrelated Thai individuals by means of polymerase chain reaction sequence-specific oligonucleotide (PCR-SSO) in which oligonucleotide probes along the stretches of HLA-A, -B, -C, -DRB1, -DQA1, and -DQB1 genes were genotyped. These 470 individuals were selected according to their regional locations, which were from North, Northeast, South, Central, and a capital city, Bangkok. Top ranked HLA alleles in Thai population include HLA-A*11:01 (26.06%), -B*46:01 (14.04%), -C* 01:02 (17.13%), -DRB1*12:02 (15.32%), -DQA1*01:01 (24.89%), and -DQB1*05:02 (21.28%). The results revealed that the distribution of HLA-pharmacogenetics alleles from the South had more HLA-B75 family that a typical HLA-B*15:02 pharmacogenetics test for SJS/TEN screening would not cover. Besides the view across the nation, when compared HLA alleles from Thai population with HLA alleles from both European and Asian countries, the distribution landscape of HLA-associated drug hypersensitivity across many countries could be observed. Consequently, this pharmacogenetics database offers a comprehensive view of pharmacogenetics marker distribution in Thailand that could be used as a reference for other Southeast Asian countries to validate the feasibility of their future pharmacogenetics deployment.https://www.frontiersin.org/article/10.3389/fphar.2020.00078/fullhuman leukocyte antigenHLA class IHLA class IIThai populationpharmacogenetic marker |
| spellingShingle | Patompong Satapornpong Patompong Satapornpong Patompong Satapornpong Pimonpan Jinda Pimonpan Jinda Thawinee Jantararoungtong Thawinee Jantararoungtong Napatrupron Koomdee Napatrupron Koomdee Chonlawat Chaichan Chonlawat Chaichan Jirawat Pratoomwun Jirawat Pratoomwun Chalitpon Na Nakorn Wichai Aekplakorn Alisa Wilantho Alisa Wilantho Chumpol Ngamphiw Chumpol Ngamphiw Sissades Tongsima Sissades Tongsima Chonlaphat Sukasem Chonlaphat Sukasem Chonlaphat Sukasem Genetic Diversity of HLA Class I and Class II Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics Frontiers in Pharmacology human leukocyte antigen HLA class I HLA class II Thai population pharmacogenetic marker |
| title | Genetic Diversity of HLA Class I and Class II Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics |
| title_full | Genetic Diversity of HLA Class I and Class II Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics |
| title_fullStr | Genetic Diversity of HLA Class I and Class II Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics |
| title_full_unstemmed | Genetic Diversity of HLA Class I and Class II Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics |
| title_short | Genetic Diversity of HLA Class I and Class II Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics |
| title_sort | genetic diversity of hla class i and class ii alleles in thai populations contribution to genotype guided therapeutics |
| topic | human leukocyte antigen HLA class I HLA class II Thai population pharmacogenetic marker |
| url | https://www.frontiersin.org/article/10.3389/fphar.2020.00078/full |
| work_keys_str_mv | AT patompongsatapornpong geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT patompongsatapornpong geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT patompongsatapornpong geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT pimonpanjinda geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT pimonpanjinda geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT thawineejantararoungtong geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT thawineejantararoungtong geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT napatrupronkoomdee geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT napatrupronkoomdee geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT chonlawatchaichan geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT chonlawatchaichan geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT jirawatpratoomwun geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT jirawatpratoomwun geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT chalitponnanakorn geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT wichaiaekplakorn geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT alisawilantho geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT alisawilantho geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT chumpolngamphiw geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT chumpolngamphiw geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT sissadestongsima geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT sissadestongsima geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT chonlaphatsukasem geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT chonlaphatsukasem geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics AT chonlaphatsukasem geneticdiversityofhlaclassiandclassiiallelesinthaipopulationscontributiontogenotypeguidedtherapeutics |